Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from...

|About: Threshold Pharmaceuticals, ... (THLD)|By:, SA News Editor

Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from drug partner Merck (MRK), which started a late-stage study of THLD's pancreatic cancer drug. TH-302 is an investigational hypoxia-targeted drug designed to be activated under severe tumor hypoxic conditions, a hallmark of many cancers.